DXGPT

What is DxGPT and who is behind it?

Foundation 29 describes DxGPT as "a free medical AI platform for diagnostic support". According to the FAQ, the foundation funds itself through "philanthropic donations, grants, and collaborative partnerships". The site is hosted on Microsoft Azure.

What does it do?

The input is free text, or an uploaded document or image. The output is a ranked list of hypotheses with the compatible symptoms and areas worth evaluating. Further functions include follow-up questions, disease information, and genetic-testing suggestions to discuss with a clinician. Language is detected automatically, and sensitive data is anonymised before processing. A beta page at dxgpt.app/beta answers general medical questions with cited sources.

The FAQ says the tool is not meant for emergencies.

What does it cost?

The web app is free: the FAQ says "DxGPT is entirely free to use". The API at pricing.dxgpt.app has a Freemium plan and bills per call, calculated daily and invoiced monthly. A diagnosis call costs about $0.022 to $0.037, a general question about $0.048 to $0.072, and document or image extraction costs extra. Endpoints include /diagnose, /medical/analyze, /ask, /questions/followup and /disease/info, and the page pitches integration into EHRs, apps and patient portals without naming an EHR vendor.

What is the regulatory status?

The FAQ says the professional version is considered medical device software, Class IIa under MDR Rule 11 "based on the information submitted to AEMPS", with the conformity assessment still to be completed. The FAQ cites no CE certificate. The FDA's 510(k) listings show nothing under Foundation 29, so the tool is not cleared for US clinical use. The site says it is "GDPR & HIPAA ready" and names no BAA, SOC 2 report or certificate.

What numbers does the vendor publish?

The pricing site reports over 1 million users, 1.7 million sessions, 1.2 million searches, and a 4.42 out of 5 rating from 18,800 votes, as of October 2026. All are self-reported, and they measure usage and satisfaction.

Homepage testimonials come from Dr. Julio Mayol (Hospital Clinico San Carlos), Dr. Juanjo Rios (Hospital La Paz) and three anonymous users. Rios says it "complements our capacity for differential diagnosis, especially in those patients with less prevalent diseases".

The verdict

DxGPT costs nothing to use, so a neurologist or internist facing an odd multi-system picture can put a case in and read its list next to their own. It is a fit for rare-disease brainstorming. A US practice that needs a cleared device, an emergency setting the FAQ rules out, or a buyer who needs a published accuracy study should not build a workflow on it.